THRU PHARMA LLC, d/b/a pharmaCline™, is a technology and pharmaceutical Company that was organized as a limited liability company in the State of Delaware on December 6, 2010. The Company’s offices are located in Sioux Falls, South Dakota, and the Company is a licensed Wholesale Drug Distributor regulated by both the U.S. Food and Drug Administration and the South Dakota Board of Pharmacy. The Company is a member of leading industry and patient-centered associations and organizations. The Company has two Divisions: Wound Care and Animal Health. The technologies and products offered are designed to meet unmet needs in these growth markets, with a heavy emphasis in wound care.
pharmaCline is currently in an SEC (Reg. D) listed Private Placement Offering available only to accredited investors. This Offering is intended to raise sufficient capital to support the national marketing rollout and sales pull-through of products in the podiatry and wound care professional markets, and the sizable retail consumer market. Products enter the professional market mainly via the large pharmaceutical distribution companies and retail pharmacies. The consumer market will be offered a patented unit dose packaging that will revolutionize the ease and effectiveness of first aid antibiotic treatment. The products will enter the direct-to-consumer market via placement in the large retail pharmacy companies that are widely integrated throughout the US economy.
The Company’s leading product, Diabecline® antibiotic, has received multiple awards for Best New Pharmaceutical during 2012. In April, receipt of the Edison Award (Bronze) recognized the innovation of the product at a ceremony in conjunction with the New York Academy of Sciences. Then in September, 2012, the product received the American Business Awards Silver medal for Best New Pharmaceutical at a ceremony in San Francisco. Then, in October, the Company attended a vendor conference at which the top pharmacy holding companies in North America and the United Kingdom selected products for shelve space in 2013. Diabecline antibiotic was voted by the diabetes and long-term care category managers of these large companies as the Best New Pharmaceutical product. The Company believes that these external validation events contributed to many of those large pharmacy holding companies becoming prospective customers of the Company.
The Company anticipates introducing at least five products over the next five years. Two antibiotic products--Diabecline® and TetraMaxx™ --are scheduled for commercialization soon as topical first aid antibiotics. The active ingredient in these products is listed with the United States Food and Drug Administration, and the products will qualify as over-the-counter (OTC) drugs authorized for sale in the United States. A third topical first aid antibiotic is scheduled for introduction into Canada, using a different active ingredient that is OTC in that country but not in the United States. Two other products are planned as prescription drugs. The first is a patent pending topical antibiotic and the second is a patented toenail thinning topical antifungal product. The earliest that these prescription products are expected to be launched is in 2015. Numerous other products are in various feasibility and testing phases, along with the Company’s launch of their animal health suite of products.
If you are an accredited investor, and have interest in additional information, please contact pharmaCline's Chief Executive Officer, Steve Keough, at firstname.lastname@example.org or at 605.271.2086 (office). Please read the complete Private Placement Memorandum and Exhibits prior to making any investment decisions.
This Summary of certain provisions of the current Private Placement Memorandum is intended only for quick reference and is not a complete presentation of all relevant information. The Memorandum and attached Exhibits describe in detail numerous aspects of the Company and its business that are material to Prospective Investors. You should read this entire Memorandum, including the attached Exhibits and any documents incorporated by reference, before making an investment decision. You should also evaluate any other documents referred to in this Memorandum, which are available to you upon request or which are otherwise material to your investment decision.